Literature DB >> 12381685

Inotropic responses to human gene 2 (B29) relaxin in a rat model of myocardial infarction (MI): effect of pertussis toxin.

Andrew R Kompa1, Chrishan S Samuel, Roger J Summers.   

Abstract

Relaxin produces powerful inotropic and chronotropic responses in isolated atria. The effect of relaxin has been examined in a rat model of cardiac failure, induced by myocardial infarction (MI). Maximum inotropic responses to isoprenaline (sham 5.4+/-0.3 mN; MI 2.6+/-0.3 mN; P<0.001) and relaxin (sham 5.1+/-0.6 mN; MI 2.8+/-0.5 mN; P=0.013) were reduced in left atria following MI. No change in chronotropic responsiveness was observed in right atria. Pertussis toxin (PTX) treatment restored inotropic responses to isoprenaline (sham 5.5+/-1.3 mN; MI 5.8+/-1.0 mN; P=0.850) but not to relaxin. Instead, PTX reduced inotropic responses to relaxin in sham animals to the same level seen in the MI group (sham 3.2+/-1.7 mN; MI 2.8+/-0.6 mN; P=0.847). In right atria, PTX treatment did not affect the maximum chronotropic response to isoprenaline, but reduced responses to relaxin in both sham and MI animals. R3 relaxin and relaxin receptor (LGR7) mRNA was present in atria and left ventricle (LV) from sham and MI animals. R3 relaxin mRNA expression was increased in atria but not LV from MI animals. LGR7 mRNA expression was reduced in atria and LV from MI animals. PTX treatment in unoperated rats increased chronotropic responses (vehicle 184.3+/-5.3 beats min(-1); PTX 211.3+/-9.5 beats min(-1); P=0.029) and produced a rightward shift in the concentration-response curve to isoprenaline in left atria. PTX reduced inotropic (vehicle 3.3+/-0.7 mN; PTX 0.8+/-0.2 mN; P=0.005) and chronotropic (vehicle 130.2+/-8.1 beats min(-1); PTX 90.6+/-11.1 beats min(-1); P=0.012) responses to relaxin. 6 In left atria, relaxin produced a small increase in cAMP compared to those produced by isoprenaline and forskolin. However, PTX treatment significantly reduced relaxin-, isoprenaline- and forskolin-stimulated cAMP accumulation. Cardiac failure in MI animals caused a reduced inotropic response to both relaxin and (-)-isoprenaline. In non-MI animals, PTX treatment also reduced inotropic responses to relaxin. Differences between responses to (-)-isoprenaline and relaxin can be explained by changes in coupling efficiency occurring at the level of adenylate cyclase.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12381685      PMCID: PMC1573542          DOI: 10.1038/sj.bjp.0704922

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  37 in total

1.  Restricted, but abundant, expression of the novel rat gene-3 (R3) relaxin in the dorsal tegmental region of brain.

Authors:  Tanya C D Burazin; Ross A D Bathgate; Mary Macris; Sharon Layfield; Andrew L Gundlach; Geoffrey W Tregear
Journal:  J Neurochem       Date:  2002-09       Impact factor: 5.372

2.  The pregnancy hormone relaxin is a player in human heart failure.

Authors:  T Dschietzig; C Richter; C Bartsch; M Laule; F P Armbruster; G Baumann; K Stangl
Journal:  FASEB J       Date:  2001-10       Impact factor: 5.191

3.  Relaxin triggers calcium transients in human granulosa-lutein cells.

Authors:  A Mayerhofer; R Engling; B Stecher; A Ecker; K Sterzik; M Gratzl
Journal:  Eur J Endocrinol       Date:  1995-04       Impact factor: 6.664

4.  Relaxin increases heart rate by modulating calcium current in cardiac pacemaker cells.

Authors:  X Han; Y Habuchi; W R Giles
Journal:  Circ Res       Date:  1994-03       Impact factor: 17.367

5.  Molecular cloning and characterization of cDNA sequences coding for rat relaxin.

Authors:  P Hudson; J Haley; M Cronk; J Shine; H Niall
Journal:  Nature       Date:  1981-05-14       Impact factor: 49.962

6.  Relaxin signalling links tyrosine phosphorylation to phosphodiesterase and adenylyl cyclase activity.

Authors:  O Bartsch; B Bartlick; R Ivell
Journal:  Mol Hum Reprod       Date:  2001-09       Impact factor: 4.025

7.  Phorbol ester, prolactin, and relaxin cause translocation of protein kinase C from cytosol to membranes in human endometrial cells.

Authors:  S S Kalbag; M S Roginsky; Z Jelveh; S Sulimovici
Journal:  Biochim Biophys Acta       Date:  1991-08-13

8.  Cardiac effects of relaxin in rats.

Authors:  H Kakouris; L W Eddie; R J Summers
Journal:  Lancet       Date:  1992-05-02       Impact factor: 79.321

9.  Relaxin increases the firing rate of supraoptic neurones and increases oxytocin secretion in the rat.

Authors:  S A Way; G Leng
Journal:  J Endocrinol       Date:  1992-01       Impact factor: 4.286

10.  Relaxin binding in the rat heart atrium.

Authors:  P L Osheroff; M J Cronin; J A Lofgren
Journal:  Proc Natl Acad Sci U S A       Date:  1992-03-15       Impact factor: 11.205

View more
  12 in total

Review 1.  The emerging role of relaxin as a novel therapeutic pathway in the treatment of chronic kidney disease.

Authors:  Jennifer M Sasser
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-07-24       Impact factor: 3.619

Review 2.  Cardiovascular effects of relaxin: from basic science to clinical therapy.

Authors:  Xiao-Jun Du; Ross A D Bathgate; Chrishan S Samuel; Anthony M Dart; Roger J Summers
Journal:  Nat Rev Cardiol       Date:  2009-11-24       Impact factor: 32.419

Review 3.  Constitutive formation of an RXFP1-signalosome: a novel paradigm in GPCR function and regulation.

Authors:  Michelle L Halls
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 4.  The actions of relaxin on the human cardiovascular system.

Authors:  Mohsin Sarwar; Xiao-Jun Du; Thomas B Dschietzig; Roger J Summers
Journal:  Br J Pharmacol       Date:  2016-07-11       Impact factor: 8.739

Review 5.  Unveiling the vasodilatory actions and mechanisms of relaxin.

Authors:  Kirk P Conrad
Journal:  Hypertension       Date:  2010-05-24       Impact factor: 10.190

Review 6.  International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides.

Authors:  Michelle L Halls; Ross A D Bathgate; Steve W Sutton; Thomas B Dschietzig; Roger J Summers
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

Review 7.  Relaxin: review of biology and potential role in treating heart failure.

Authors:  Sam L Teichman; Elaine Unemori; John R Teerlink; Gad Cotter; Marco Metra
Journal:  Curr Heart Fail Rep       Date:  2010-06

8.  Relaxin promotes growth and maturation of mouse neonatal cardiomyocytes in vitro: clues for cardiac regeneration.

Authors:  Silvia Nistri; Alessandro Pini; Chiara Sassoli; Roberta Squecco; Fabio Francini; Lucia Formigli; Daniele Bani
Journal:  J Cell Mol Med       Date:  2012-03       Impact factor: 5.310

9.  Upregulation of relaxin after experimental subarachnoid hemorrhage in rabbits.

Authors:  Yuichiro Kikkawa; Satoshi Matsuo; Ryota Kurogi; Akira Nakamizo; Masahiro Mizoguchi; Tomio Sasaki
Journal:  Biomed Res Int       Date:  2014-07-16       Impact factor: 3.411

10.  Relaxin family peptide receptors Rxfp1 and Rxfp2: mapping of the mRNA and protein distribution in the reproductive tract of the male rat.

Authors:  Marcelo Filonzi; Laís C Cardoso; Maristela T Pimenta; Daniel B C Queiróz; Maria C W Avellar; Catarina S Porto; Maria F M Lazari
Journal:  Reprod Biol Endocrinol       Date:  2007-07-10       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.